Advanced malignant solid neoplasm develops as a result of multifactorial etiologies that vary by cancer type; however, it is strongly associated with a high-grade (G3) clinical stage and is considered a 'late-phase' disease with poor clinical outcomes.
The lifetime incidence and prevalence of ASIN among all men and women in the United States is approximately 1% per year. In men, the incidence peaks in the 80- to 90-year-old age group.
Advanced malignant solid neoplasm is diagnosed and treated at an advanced stage in 80% of patients, as is the case with solid tumors in patients undergoing palliative therapy.
Results from a recent clinical trial is limited to a small number of patients. Results from a recent clinical trial are preliminary so should undergo prospective validation.
The data obtained from our study show that the average age for new presentation with AMSN by gender is 69 for men and 66 years old for women. Because our analysis was limited, we cannot claim that our results are an accurate reflection of all patients with AMSN in Germany. However, we suggest that the average age for new appearance of AMSN in Germany is 69 years old for men and 66 years old for women.
Given that several previously developed cancer therapies have deleterious effects on QOL and survival, clinicians should consider administering a cancer drug that has a potential therapeutic benefit and improves QOL.
Treatment for advanced malignant diseases may be more complicated than for other malignancy types. The most commonly used treatments by metastatic solid tumors are chemotherapy using a combination of agents, radiotherapy, palliative care with symptom management, or systemic therapies.
The sign of a high-grade lesion may be more specific for advanced malignant solid neoplasm (AMSN) than it is for solid malignancy. However, its specificity for AMSN cannot be as high as that of solid-malignancy for some high-grade lesions. Therefore, the overall accuracy of these signs is not sufficiently good for application in clinical practice.
Advanced malignant solid neoplasm is a rare diagnosis in lung cancer. Most of the patients with lung cancer are diagnosed after the disease has already progressed at presentation, which suggests a poor prognosis. Advanced solid neoplasm is a rare, yet important and complex disease, as its clinical behavior can be quite distinct from non-solid tumors of the lung.
Veliparib was first approved for use in advanced ovarian cancer in 2007. Prior to this approval, there were no other clinical trials evaluating the use of veliparib in ovarian cancer. Thus, further study examining the role of veliparib in this setting is needed.
In people with advanced solid tumors who are either refractory to, or relapsed from, previous chemotherapy, add-on veliparib to a second line treatment, either as a first-line treatment or after the first progression or relapse, did not significantly prolong progression-free survival in comparison with the placebo, in terms of OS (HR = 0.96; 95% CI: 0.81 to 1.12; p = 0.52), or progression-free survival. Overall survival was not significantly prolonged by add-on veliparib in comparison with placebo (HR = 0.98; 95% CI: 0.81 to 1.15; p = 0.59).